238 related articles for article (PubMed ID: 26047789)
1. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.
Ruseva MM; Peng T; Lasaro MA; Bouchard K; Liu-Chen S; Sun F; Yu ZX; Marozsan A; Wang Y; Pickering MC
J Am Soc Nephrol; 2016 Feb; 27(2):405-16. PubMed ID: 26047789
[TBL] [Abstract][Full Text] [Related]
2. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
3. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
Huang Y; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2008 Dec; 181(11):8068-76. PubMed ID: 19017999
[TBL] [Abstract][Full Text] [Related]
4. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
5. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
Rohrer B; Long Q; Coughlin B; Wilson RB; Huang Y; Qiao F; Tang PH; Kunchithapautham K; Gilkeson GS; Tomlinson S
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3056-64. PubMed ID: 19264882
[TBL] [Abstract][Full Text] [Related]
6. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
7. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
8. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
Fridkis-Hareli M; Storek M; Or E; Altman R; Katti S; Sun F; Peng T; Hunter J; Johnson K; Wang Y; Lundberg AS; Mehta G; Banda NK; Michael Holers V
Mol Immunol; 2019 Jan; 105():150-164. PubMed ID: 30513451
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.
Wang X; Van Lookeren Campagne M; Katschke KJ; Gullipalli D; Miwa T; Ueda Y; Wang Y; Palmer M; Xing G; Song WC
J Am Soc Nephrol; 2018 Aug; 29(8):2053-2059. PubMed ID: 29895552
[No Abstract] [Full Text] [Related]
10. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
11. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.
Ruseva MM; Takahashi M; Fujita T; Pickering MC
Clin Exp Immunol; 2014 Apr; 176(1):84-92. PubMed ID: 24279761
[TBL] [Abstract][Full Text] [Related]
12. Proof of concept of a new plasma complement Factor H from waste plasma fraction.
Mori F; Pascali G; Berra S; Lazzarotti A; Panetta D; Rocchiccioli S; Ceccherini E; Norelli F; Morlando A; Donadelli R; Clivio A; Farina C; Noris M; Salvadori PA; Remuzzi G
Front Immunol; 2024; 15():1334151. PubMed ID: 38919628
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases].
He RJ; Xiao HJ; Wang SX; Guan N; Yao Y; Ding J
Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154
[TBL] [Abstract][Full Text] [Related]
14. Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy.
Barbour TD; Ling GS; Ruseva MM; Fossati-Jimack L; Cook HT; Botto M; Pickering MC
Kidney Int; 2016 Apr; 89(4):823-32. PubMed ID: 26924054
[TBL] [Abstract][Full Text] [Related]
15. [C3 glomerulopathy].
Chauvet S; Servais A; Frémeaux-Bacchi V
Nephrol Ther; 2014 Apr; 10(2):78-85. PubMed ID: 24508002
[TBL] [Abstract][Full Text] [Related]
16. Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase.
Paixão-Cavalcante D; Hanson S; Botto M; Cook HT; Pickering MC
Mol Immunol; 2009 Jun; 46(10):1942-50. PubMed ID: 19411110
[TBL] [Abstract][Full Text] [Related]
17. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.
Nichols EM; Barbour TD; Pappworth IY; Wong EK; Palmer JM; Sheerin NS; Pickering MC; Marchbank KJ
Kidney Int; 2015 Dec; 88(6):1314-1322. PubMed ID: 26221753
[TBL] [Abstract][Full Text] [Related]
18. Update on C3 glomerulopathy.
Barbour TD; Ruseva MM; Pickering MC
Nephrol Dial Transplant; 2016 May; 31(5):717-25. PubMed ID: 25326473
[TBL] [Abstract][Full Text] [Related]
19. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
20. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
